Cancer Immunology, Immunotherapy

, Volume 56, Issue 9, pp 1429–1442

Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment

  • Christoph Bergmann
  • Laura Strauss
  • Reinhard Zeidler
  • Stephan Lang
  • Theresa L. Whiteside
Original Article



Chronic inflammation and cancer development are associated with dysregulated immune responses and the presence of regulatory T cells (Treg). To study the role of Treg in tumor cell escape from immune surveillance, an in vitro model simulating the tumor microenvironment and promoting the induction and expansion of IL-10+ Treg type 1 (Tr1) was established.


An in vitro co-culture system (IVA) included an irradiated head and neck squamous cell carcinoma cell line, immature dendritic cells (iDC), CD4+CD25T cells and cytokines, IL-2 (10 IU/ml), IL-10 (20 IU/ml), IL-15 (20 IU/ml) ± 1 nM rapamycin. Autologous iDC and CD4+CD25 T cells were obtained from the peripheral blood of 15 normal donors. Co-cultures were expanded for 10 days. Proliferating lymphocytes were phenotyped by multi-color flow cytometry. Their suppressor function was measured in CFSE inhibition assays ± neutralizing anti-IL-10 mAb and using transwell cultures. Culture supernatants were tested for IL-4, IL-10, TGF-β and IFN-γ in ELISA.


In the IVA, low doses of IL-2, IL-10 and IL-15 promoted induction and expansion of CD3+CD4+CD25IL2Rβ+IL2Rγ+FoxP3+CTLA-4+IL-10+ cells with suppressor activity (mean suppression ± SD = 58 ± 12%). These suppressor cells produced IL-10 (mean ± SD = 535 ± 12 pg/ml) and TGF-β (mean ± SD = 512 ± 38 pg/ml), but no IL-4 or IFN-γ. Suppressor function of co-cultures correlated with the percent of expanding IL-10+ Tr1 cells (r= 0.9; P < 0.001). The addition of rapamycin enriched Tr1 cells in all co-cultures. Neutralizing anti-IL-10 mAb abolished suppressive activity. Suppression was cell-contact independent.


The tumor microenvironment promotes generation of Tr1 cells which have the phenotype distinct from that of CD4+CD25highFoxP3+ nTreg and mediate IL-10 dependent immune suppression in a cell-contact independent manner. Tr1 cells may play a critical role in cancer progression.


Tr1 cells Treg HNSCC Immune suppression Tumor escape Rapamycin 


  1. 1.
    Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14:483–510PubMedCrossRefGoogle Scholar
  2. 2.
    Assenmacher M, Lohning M, Scheffold A, Richter A, Miltenyi S, Schmitz J, Radbruch A (1998) Commitment of individual Th1-like lymphocytes to expression of IFN-gamma versus IL-4 and IL-10: selective induction of IL-10 by sequential stimulation of naive Th cells with IL-12 and IL-4. J Immunol 161:2825–2832PubMedGoogle Scholar
  3. 3.
    Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal Malefyt R, de Vries JE, Roncarolo MG (1994) High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179:493–502PubMedCrossRefGoogle Scholar
  4. 4.
    Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG (2002) Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 32:2237–2245PubMedCrossRefGoogle Scholar
  5. 5.
    Baecher-Allan C, Hafler DA (2004) Suppressor T cells in human diseases. J Exp Med 200:273–276PubMedCrossRefGoogle Scholar
  6. 6.
    Baecher-Allan C, Anderson DE (2006) Regulatory cells and human cancer. Semin Cancer Biol 16:98–105PubMedCrossRefGoogle Scholar
  7. 7.
    Barchet W, Price JD, Cella M, Colonna M, MacMillan SK, Cobb JP, Thompson PA, Murphy KM, Atkinson JP, Kemper C (2006) Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood 107:1497–1504PubMedCrossRefGoogle Scholar
  8. 8.
    Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A (2002) In vitro generation of interleukin 10-producing regulatory CD4 (+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195:603–616PubMedCrossRefGoogle Scholar
  9. 9.
    Battaglia M, Gregori S, Bacchetta R, Roncarolo MG (2006) Tr1 cells: from discovery to their clinical application. Semin Immunol 18:120–127PubMedCrossRefGoogle Scholar
  10. 10.
    Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E, Roncarolo MG (2006) Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55:40–49PubMedCrossRefGoogle Scholar
  11. 11.
    Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253–257PubMedCrossRefGoogle Scholar
  12. 12.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRefGoogle Scholar
  13. 13.
    de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915–924PubMedCrossRefGoogle Scholar
  14. 14.
    Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ (2002) Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 196:851–857PubMedCrossRefGoogle Scholar
  15. 15.
    Giri JG, Anderson DM, Kumaki S, Park LS, Grabstein KH, Cosman D (1995) IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 57:763–766PubMedGoogle Scholar
  16. 16.
    Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737–742PubMedCrossRefGoogle Scholar
  17. 17.
    Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB, Whiteside TL (1989) Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 49:5167–5175PubMedGoogle Scholar
  18. 18.
    Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL (1998) IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 28:2780–2790PubMedCrossRefGoogle Scholar
  19. 19.
    Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T (2002) NOD/SCID/gamma(c) (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100:3175–3182PubMedCrossRefGoogle Scholar
  20. 20.
    Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4 (+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213–1222PubMedCrossRefGoogle Scholar
  21. 21.
    Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG (2001) IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 166:5530–5539PubMedGoogle Scholar
  22. 22.
    Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG (2005) Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105:1162–1169PubMedCrossRefGoogle Scholar
  23. 23.
    Levings MK, Roncarolo MG (2005) Phenotypic and functional differences between human CD4+CD25+ and type 1 regulatory T cells. Curr Top Microbiol Immunol 293:303–326PubMedCrossRefGoogle Scholar
  24. 24.
    Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203:1701–1711PubMedCrossRefGoogle Scholar
  25. 25.
    Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665–674PubMedCrossRefGoogle Scholar
  26. 26.
    Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043–1051PubMedCrossRefGoogle Scholar
  27. 27.
    Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007–1008PubMedCrossRefGoogle Scholar
  28. 28.
    Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50PubMedCrossRefGoogle Scholar
  29. 29.
    Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3CD25CD4 natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27PubMedCrossRefGoogle Scholar
  30. 30.
    Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920PubMedCrossRefGoogle Scholar
  31. 31.
    Shevach EM (2004) Fatal attraction: tumors beckon regulatory T cells. Nat Med 10:900–901PubMedCrossRefGoogle Scholar
  32. 32.
    Stassen M, Schmitt E, Jonuleit H (2004) Human CD(4+)CD(25+) regulatory T cells and infectious tolerance. Transplantation 77:S23–S25PubMedCrossRefGoogle Scholar
  33. 33.
    Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH (1997) Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159:4772–4780PubMedGoogle Scholar
  34. 34.
    Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A (2007) Selective in vitro survival of naturally occuring human CD4+CD25+FOXP3+ regulatory T cells with rapamycin. J Immunol 178(1):320–329PubMedGoogle Scholar
  35. 35.
    Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K, Nakamura M, Takeshita T (1996) The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14:179–205PubMedCrossRefGoogle Scholar
  36. 36.
    Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H et al (1995) Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268:1472–1476PubMedCrossRefGoogle Scholar
  37. 37.
    Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15PubMedCrossRefGoogle Scholar
  38. 38.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772PubMedGoogle Scholar
  39. 39.
    You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L (2006) Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 212:185–202PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang M, Tang H, Guo Z, An H, Zhu X, Song W, Guo J, Huang X, Chen T, Wang J, Cao X (2004) Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 5:1124–1133PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Christoph Bergmann
    • 1
  • Laura Strauss
    • 1
  • Reinhard Zeidler
    • 2
  • Stephan Lang
    • 3
  • Theresa L. Whiteside
    • 1
  1. 1.Research Pavilion at the Hillman Cancer CenterUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  2. 2.Department of OtorhinolaryngologyLudwig-Maximilians-University of MunichMunichGermany
  3. 3.Department of OtorhinolaryngologyUniversity of Duisburg-EssenEssenGermany

Personalised recommendations